Published in Medical Letter on the CDC and FDA, April 2nd, 2006
Company president, CEO and chief scientific officer Jacqueline Shan unveiled the company's future U.S. growth strategy at its annual general meeting in Edmonton.
The company plans to seek U.S. Food and Drug Administration (FDA) approval for COLD-fX as an OTC (over the counter) drug for the prevention or reduction of the risk of cold and flu. Shan said, "To obtain this approval we plan to conduct phase III drug trials. OTC drug approval will allow us to make very specific medical claims and will afford us label exclusivity which will further enhance our ability to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA